Here is some information about the types of second opinions we offer and how to request one.
About 80 percent of all childhood leukemia is acute lymphoblastic leukemia (ALL), also called acute lymphocyte or lymphoid leukemia. There are about 3,000 cases of ALL in children and youth up to age 21 each year in the U.S.
Acute lymphoblastic leukemia in children has one of the highest cure rates and we are specially equipped at The Children's Hospital of Philadelphia to diagnose and effectively treat this type of leukemia and all childhood leukemias.
Through our Pediatric Leukemia and Lymphoma Program in partnership with our Pediatric Blood and Marrow Transplantation Program, we bring together a team of experts in your child's particular type of leukemia, to develop a comprehensive leukemia treatment plan to ensure the best possible outcome.
Acute lymphoblastic leukemia in children affects the immature forms of white blood cells called lymphocytes. There are two basic types of lymphocytes, B-lymphocytes and T-lymphocytes, and their immature forms are the source of the two corresponding subsets of ALL, T-ALL and B- or pre-B ALL. The job of lymphocytes is to identify and combat foreign substances, bacteria and viruses in the body. In ALL, the bone marrow makes too many immature lymphocytes (called lymphoblasts) that do not mature correctly. The lymphoblasts overproduce and crowd out normal blood-forming cells. Immature blood cells (blasts) do not have the ability to fight infection.
CTL019, a clinical trial of T cell therapy for patients with B cell cancers such as acute lymphoblastic leukemia, B cell non-Hodgkin lymphoma (NHL), and the adult disease chronic lymphocytic leukemia (CLL), has shown exciting early results for the first patients to be treated.
This clinical trial, formerly referred to as CART19, uses immune cells taken from a patient's own blood, called T cells. These cells are genetically modified to express a protein which will recognize and bind to a target called CD19, which is found on cancerous B cells. Here is how CTL019 works:
While the numbers of patients treated so far are small — 10 adults with chronic lymphocytic leukemia (CLL), and 2 children with acute lymphoblastic leukemia (ALL) — scientists at The Children’s Hospital of Philadelphia and the University of Pennsylvania have been able to show:
Scientists at The Children’s Hospital of Philadelphia and the University of Pennsylvania are very hopeful that CTL019 could in the future be an effective therapy for patients with B cell cancers. However, because so few patients have been treated, it is critical that more adult and pediatric patients are enrolled in the study to determine whether a larger group of patients with B cell cancers will have the same response.
Review the following options for contacting CHOP about CTL019.
Existing patients or family members, please call
To schedule an initial appointment or request a 2nd opinion